Suppr超能文献

术前使用多柔比星联合异环磷酰胺治疗四肢原发性软组织肉瘤。

Preoperative doxorubicin plus ifosfamide in primary soft-tissue sarcomas of the extremities.

作者信息

Azzarelli A, Quagliuolo V, Casali P, Fissi S, Montalto F, Santoro A

机构信息

Division of Surgical Oncology, Istituto Nazionale Tumori, Milan, Italy.

出版信息

Cancer Chemother Pharmacol. 1993;31 Suppl 2:S210-2.

PMID:8453700
Abstract

A total of 51 patients with large, primary, high-grade soft-tissue sarcomas of the extremities were treated at our institute with two preoperative and three postoperative cycles of doxorubicin plus ifosfamide/mesna. Preoperative doxorubicin was given intra-arterially for lesions of the lower extremities. Of 47 evaluable patients, 22 (47%) showed clinical responses and 21 (45%), pathologic responses. Clinical and pathologic responses, however, were not necessarily coincident in the same patient. Conservative limb-sparing surgery was performed in 41 cases (87%), and in 4 cases amputation was avoided as a result of the local improvement induced by chemotherapy. Local recurrence occurred in 12 cases (25%), 3 of which required further amputation. Although the follow-up period was only 28 months, the 4-year actuarial survival was 91% and the 4-year metastasis-free value was 69%. An evident difference existed between patients who showed a documented clinical response to chemotherapy and those who did not, the 4-year metastasis-free value being 85% and 59% (P = 0.1), respectively. Adjuvant preoperative chemotherapy may allow for limb-salvage surgical procedures in selected cases.

摘要

我院共对51例原发性、高级别、肢体大软组织肉瘤患者进行了治疗,给予术前2个周期及术后3个周期的阿霉素加异环磷酰胺/美司钠治疗。对于下肢病变,术前阿霉素采用动脉内给药。在47例可评估患者中,22例(47%)显示出临床反应,21例(45%)显示出病理反应。然而,临床反应和病理反应在同一患者中不一定一致。41例(87%)患者接受了保肢手术,4例因化疗诱导的局部改善而避免了截肢。12例(25%)出现局部复发,其中3例需要进一步截肢。尽管随访期仅28个月,但4年精算生存率为91%,4年无转移率为69%。对化疗有记录的临床反应的患者与无临床反应的患者之间存在明显差异,4年无转移率分别为85%和59%(P = 0.1)。辅助性术前化疗在某些病例中可能允许进行保肢手术。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验